ArticleFrontiers in public health2022
Epidemiology, Drug Susceptibility, and Clinical Risk Factors in Patients With Invasive Aspergillosis.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Pooled it
- Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis.Frontiers in pharmacology · 2024Pooled it
- COVID-19-Associated Fungal Co-Infections: Pathogenesis, Diagnostics, Biomarkers, and Therapeutic Strategies.Journal of clinical medicine · 2026Review
- Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Journal of fungi (Basel, Switzerland) · 2026Review
- BeyondAntimicrobial agents and chemotherapy · 2026Article
- Investigation of azole resistance inJournal of medical microbiology · 2026Article
- Synergistic effects of S100 calcium-binding protein A12 combined with Pentraxin 3 in invasive pulmonary aspergillosis and their clinical application prospects.Frontiers in cellular and infection microbiology · 2026Review
- Isavuconazole-Amphotericin B and Isavuconazole-Caspofungin In Vitro Synergic Activity Against Invasive Pulmonary Aspergillosis Molds Isolates.Antibiotics (Basel, Switzerland) · 2025Article
- Biofilm Formation, c-di-GMP Production, and Antimicrobial Resistance in Staphylococcal Strains Isolated from Prosthetic Joint Infections: A Pilot Study in Total Hip and Knee Arthroplasty Patients.International journal of molecular sciences · 2025Article
- Azole Resistance inJournal of fungi (Basel, Switzerland) · 2025Article
- Comprehensive Review of Environmental Surveillance for Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Occurrence of Pathogenic and Allergenic Molds in the Outdoor and Indoor Environment of a Major Hospital and Molecular Epidemiology ofJournal of fungi (Basel, Switzerland) · 2025Article
- Impact of CD11cFrontiers in fungal biology · 2025Article
- Molecular Identification ofInfection and drug resistance · 2025Article
- Research advances and public health strategies in China on WHO priority fungal pathogens.Mycology · 2025Review
- Epidemiology and Antifungal Susceptibilities of Clinically IsolatedInfection and drug resistance · 2024Article
- Antifungal Susceptibility and Genotypic Analysis ofInfection and drug resistance · 2024Article
- Epidemiology and Azole Resistance of Clinical Isolates ofInfection and drug resistance · 2024Article
- Epidemiology of Clinically SignificantInfection and drug resistance · 2023Article
- Loss of the mammalian G-protein coupled receptor, G2A, modulates severity of invasive pulmonary aspergillosis.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the Methods: In the present study, 156 Results: The Conclusions: The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.